Skip to content
Topics
Breast Cancer
Chronic Lymphocytic Leukemia
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Conference Coverage
ASCO 2026 Show Dailies
ASCO GI 2026 Conference Coverage
ASH 2025 Conference Coverage
JADPRO 2025 Conference Coverage
Expert Perspectives
Expert Perspectives in Bladder Cancers
Expert Perspectives in GI Cancers
Expert Perspectives in Multiple Myeloma
Expert Perspectives in NET
Expert Perspectives in RCC
Patient Programs
Treatment Perspectives in Multiple Myeloma
Dialogues in Multiple Myeloma
FAQ Brochure: Multiple Myeloma
About
Advertise
Contact Us
Topics
Breast Cancer
Chronic Lymphocytic Leukemia
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Conference Coverage
ASCO 2026 Show Dailies
ASCO GI 2026 Conference Coverage
ASH 2025 Conference Coverage
JADPRO 2025 Conference Coverage
Expert Perspectives
Expert Perspectives in Bladder Cancers
Expert Perspectives in GI Cancers
Expert Perspectives in Multiple Myeloma
Expert Perspectives in NET
Expert Perspectives in RCC
Patient Programs
Treatment Perspectives in Multiple Myeloma
Dialogues in Multiple Myeloma
FAQ Brochure: Multiple Myeloma
About
Advertise
Contact Us
Subscribe
CheckMate9-ER Trial: Outcomes Across Risk Subgroups and Sites of Metastases
Learn how cabozantinib plus nivolumab performed in high-risk advanced renal cell carcinoma, including patients with liver, lung, or bone metastases.
MORE
Expert Perspectives in RCC
CheckMate-9ER Trial: How Cabozantinib+Nivolumab Preserves Quality of Life in Advanced RCC
Dr. Vincent Xu discusses the safety and tolerability outcomes from the CheckMate-9ER trial, which evaluated the use of cabozantinib+nivolumab in the treatment of advanced renal cell carcinoma.
CheckMate-9ER Trial: Safety and Tolerability Outcomes
Dr. Vincent Xu discusses the safety and tolerability outcomes from the CheckMate-9ER trial, which evaluated the use of cabozantinib+nivolumab in the treatment of advanced renal cell carcinoma.
CheckMate-9ER Trial Update: Five-year Follow-up Data on Advanced Renal Cell Carcinoma
Explore five-year CheckMate-9ER results for cabozantinib plus nivolumab in previously untreated advanced renal cell carcinoma.
Efficacy of First- and Second-line Cabozantinib Treatment in Advanced RCC
Dr. Michael Devitt discusses the efficacy of cabozantinib as a first- and second-line treatment option for patients with advanced renal cell carcinoma.
